Search | Clinical Trials Finder

Conditions: Ovarian Function, Preservation of Ovarian Function
Interventions: GnRH antagonist; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 10 Years to 21 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Prostate Cancer
Interventions: Docetaxel, ADT, Abiraterone; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infertility, Diminished Ovarian Reserve, IVF
Interventions: Timing of injectable gonadotropins; Procedure
Lead sponsor: Northwell Health; Other
Eligibility: 20 Years to 45 Years · Female only
Enrollment: 142 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Ovarian Hyperstimulation Syndrome
Interventions: Leuprolide acetate; Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 20 Years to 39 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Prostate Cancer, Cancer of the Prostate
Interventions: Ethos Varian treatment system, Adaptive stereotactic body radiotherapy, Androgen deprivation therapy; Device · Radiation · Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older · Male only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Prostate Cancer
Interventions: Prednisone, Apalutamide, Abiraterone Acetate, LHRH Agonist or Antagonist; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 5
States / cities: Boston, Massachusetts • Milford, Massachusetts • South Weymouth, Massachusetts

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel, Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2023
U.S. locations: 58
States / cities: Chandler, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more

Conditions: Prostatic Neoplasms
Interventions: Abemaciclib, Darolutamide, LHRH agonist/antagonist; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Springdale, Arkansas • Mineola, New York • New York, New York

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Prostate Cancer Metastatic
Interventions: ARV-766, Abiraterone, Corticosteroid (e.g., prednisone/prednisolone), Androgen Deprivation Therapy (ADT); Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 17
States / cities: Duarte, California • La Jolla, California • Santa Monica, California + 14 more

Conditions: Implantation, Embryo
Interventions: Leuprolide, Ganirelix; Drug
Lead sponsor: Kelly, Maureen, M.D.; Individual
Eligibility: 18 Years to 52 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions: Tulmimetostat, Darolutamide, Abiraterone, Prednisone/Prednisolone, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 181 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 8
States / cities: Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more

Conditions: Prostate Cancer
Interventions: Prostate Fossa Radiotherapy, Pelvic nodal Radiotherapy, Androgen Deprivation Therapy (ADT); Radiation · Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Hormone-Sensitive Prostate Cancer
Interventions: Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT), Placebo; Biological · Drug · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Anchorage, Alaska • Duarte, California • Los Angeles, California + 22 more

Conditions: Endometriosis
Interventions: NBI-56418 (GnRH antagonist), placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 15
States / cities: Phoenix, Arizona • San Diego, California • San Ramon, California + 12 more

Conditions: Fertility
Interventions: Bravelle and Menopur, Agonist, Antagonist; Drug
Lead sponsor: Main Line Fertility Center; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bryn Mawr, Pennsylvania

Conditions: Prostate Cancer, Oligometastasis, Oligorecurrence, Recurrent Prostate Cancer, Metastatic Prostate Cancer, De Novo Prostate Cancer
Interventions: PET-directed Local Therapy using Surgery, PET-directed Local Therapy using Radiation, Salvage Local Therapy for locally recurrent disease, Goserelin, Histrelin, Leuprolide & Triptorelin, ADT + Nilutamide, Flutamide, & Bicalutamide, Degarelix & Relugolix, ADT + Docetaxel +/- prednisone, ADT + Abiraterone + Prednisone, ADT + Abiraterone + Methylprednisolone, ADT + Apalutamide, ADT + Enzalutamide, Prostate-directed Radiation for De novo oligometastatic prostate cancer; Procedure · Radiation · Other + 1 more
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 464 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 20
States / cities: Long Beach, California • West Los Angeles, California • Washington D.C., District of Columbia + 17 more

Conditions: Prostate Cancer, Bone Metastases, Prostate Neoplasms
Interventions: LHRH agonist/antagonist, Bicalutamide, Radium-223 dichloride; Drug · Radiation
Lead sponsor: Ajjai Alva, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 12
States / cities: Phoenix, Arizona • Peoria, Illinois • Indianapolis, Indiana + 8 more

Conditions: Prostate Cancer
Interventions: Apalutamide, Placebo, Androgen Deprivation Therapy (ADT); Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,052 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2027
U.S. locations: 39
States / cities: Homewood, Alabama • Tucson, Arizona • San Bernardino, California + 36 more

Conditions: Metastatic Hormone Sensitive Prostate Cancer
Interventions: Enzalutamide, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 34
States / cities: Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more

Conditions: Metastatic Hormone-sensitive Prostate Cancer
Interventions: Darolutamide (BAY1841788, Nubeqa), ADT; Drug · Other
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 31
States / cities: Homewood, Alabama • Tucson, Arizona • Los Angeles, California + 24 more

Conditions: Prostate Cancer
Interventions: Cabozantinib, Androgen Ablation Therapy; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Male only
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer
Interventions: Standard ADT, Dovitinib; Drug
Lead sponsor: Oscar Goodman, Jr.; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
Interventions: Abiraterone, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib; Drug · Radiation · Biological
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Search by objective public record fields.

Effect of Cetrorelex Acetate on Ovarian Function in Women Undergoing Chemotherapy

Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone

The LUTEAL Trial: Luteal Stimulation vs. Estrogen Priming Protocol

The Use of GnRH Agonist Trigger in the Prevention of OHSS

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer

Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT

Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer

Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

A Novel Approach to Endometrial Preparation in Recipients of Donor Eggs

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

Endometriosis Trial: Study of NBI-56418 in Endometriosis

Effect of GnRH Antagonist vs Agonist Long on IVF Outcome, Peak Estradiol Level,and Duration of Stimulation

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

A Study to Learn How Well Darolutamide Administered Together With Androgen Deprivation Therapy (ADT) Works in Men With Metastatic Hormone-sensitive Prostate Cancer. Results Will be Compared With ADT Alone From a Previously Conducted Study.

Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer

A Study of Dovitinib With Androgen Deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer Receiving Primary ADT

Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer (FAALCON)